Bayer Saddles Up For Bicycle Radioconjugate Pact
Second Big Pharma Partner In Two Months For UK Biotech
The German major is paying $45m upfront to get access to Bicycle’s synthetic peptides for the discovery and development of multiple targeted radioconjugates in oncology.
You may also be interested in...
Deal Watch: Gilead Grows Oncology, Inflammation Pipeline With XinThera Buy
The XinThera deal gives Gilead multiple PARP1 and MK2 inhibitors. Also, Roche licenses a HER2 kinase inhibitor from Zion, Amgen partners with TScan in Crohn’s disease and Baxter sells the last of its biopharma operations – a CDMO business – for $4.5bn.
Xarelto Declines Are New Normal At Bayer
Sales of the blockbuster Factor Xa blood thinner Xarelto declined more steeply than was expected but Bayer’s second biggest seller Eylea is still performing well.
Deal Watch: Vertex Calls On CRISPR Yet Again, Now To Collaborate On Type 1 Diabetes
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.